Study: 3 Doses of This Vaccine Neutralized "Omicron"

French biotechnology company Valneva announced on Wednesday that preliminary studies showed that 3 doses of its candidate vaccine for COVID-19 neutralized the "Omicron" variant. It added that all tested vaccine samples produced antibodies that successfully neutralized the original virus and the Delta variant, while 87% of the samples were able to neutralize the "Omicron" variant. The company's chief medical officer, Juan Carlos Garmendia, stated, "We are extremely pleased with these results," noting that they supported previous trial findings that showed a better immune response after receiving two doses of the vaccine. Valneva expects to receive regulatory approvals for its vaccine within two months or slightly longer. If the vaccine is authorized in Europe, vaccine deliveries are expected to begin there in April.